ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Thursday

ALX Oncology (NASDAQ:ALXO) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

ALX Oncology Trading Down 6.4 %

ALX Oncology stock opened at $1.03 on Tuesday. The company’s fifty day simple moving average is $1.44 and its 200-day simple moving average is $1.65. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a 12 month low of $0.96 and a 12 month high of $17.83. The stock has a market cap of $54.33 million, a P/E ratio of -0.35 and a beta of 0.96.

Wall Street Analyst Weigh In

ALXO has been the subject of a number of recent analyst reports. UBS Group decreased their price target on shares of ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a report on Monday, January 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. HC Wainwright dropped their price objective on ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, January 24th. Finally, Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $3.05.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.